Pharmaceutical composition for preventing or treating ocular surface disease
US9695218B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 27, 2015 |
| Grant date | Jul 4, 2017 |
| Priority date | — |
| Expiry date | Dec 27, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition for preventing or treating an ocular surface disease is disclosed, wherein the pharmaceutical composition includes, as an active component, collagen type II α1 based peptide SEQ ID NO: 2 isolated from chondrocyte-derived extracellular matrix (CDEM). In an alkaline burn animal mode treated with peptide SEQ ID NO: 2, the occurrence of corneal opacification is reduced as well as the expression of angiogenic factors. In addition, the expression of inflammatory markers is reduced while the expression of inflammation-inducing factor is suppressed. The peptide SEQ ID NO: 2 may be applied to a pharmaceutical composition for preventing or treating an ocular surface disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.